We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Lenalidomide‐associated progressive multifocal leukoencephalopathy.
- Authors
Nishimura, Kazutaka; Iwai, Yuta; Yabuki, Mariko; Fuse, Hiroe; Nakamichi, Kazuo; Takahashi, Kenta; Suzuki, Tadaki; Saijo, Masayuki; Fukushima, Takeshi; Kuwabara, Satoshi
- Abstract
Background: Lenalidomide, an analogue of thalidomide, is frequently used to treat multiple myeloma (MM). Progressive multifocal leukoencephalopathy (PML) is an infectious disease of the central nervous system caused by the reactivation of the JC polyomavirus. Only a few reports have described PML in patients receiving lenalidomide therapy. Case presentation: A 76‐year‐old man with MM presented progressive visual and cognitive impairment during lenalidomide administration. Magnetic resonance imaging showed a lesion in the right parietal lobe. Brain biopsy confirmed the diagnosis of PML. Lenalidomide therapy was discontinued, and oral mefloquine was commenced. He was alive more than 1 year later with mild neurologic decline. Conclusions: Although rare, lenalidomide‐induced PML should be considered in myeloma patients treated with lenalidomide.
- Subjects
PROGRESSIVE multifocal leukoencephalopathy; JOHN Cunningham virus; CENTRAL nervous system diseases; MAGNETIC resonance imaging; PARIETAL lobe; MULTIPLE myeloma; LENALIDOMIDE
- Publication
Clinical & Experimental Neuroimmunology, 2021, Vol 12, Issue 1, p63
- ISSN
1759-1961
- Publication type
Article
- DOI
10.1111/cen3.12606